MS Patient Website to Provide Most Extensive On-Site Coverage at AAN

American Academy of Neurology hosts the largest North American gathering of MS researchers

  • Share on TwitterShare on FacebookShare on Google+Share on LinkedInEmail a friend
American Academy of Neurology annual meeting
It’s an important event and we’re going to provide the most extensive on-site news coverage. We need to provide up-to-date information to the hundreds of people who access MSology every day.

San Diego, CA (PRWEB) March 12, 2013

MSology, the website for people with multiple sclerosis (MS), will expand its regular news coverage to provide daily reports during the week-long annual meeting of the American Academy of Neurology (AAN).

    The AAN meeting will be held March 16-23 and is the largest gathering of neurologists in North America. “The AAN meeting gives us a preview of the latest MS research,” says Anne St-Michel, publisher of MSology. “It’s an important event and we’re going to provide the most extensive on-site news coverage. We need to provide up-to-date information to the hundreds of people who access MSology every day.”

    MSology debuted last year as a free information site offering the latest research news on MS, tips on living with the disease, and practical advice to help in making decisions. The website also provides in-depth articles, such as the recent piece addressing whether injectable therapies will continue to be used as more oral and infusion drugs become available to treat MS.
    New MS research will be presented on four key days, and MSology will be on hand in San Diego, CA, to provide daily coverage. MSology Editor Steven Manners will also Tweet throughout the conference on MSology’s Twitter account (@MSology).

    “We need to bring home the important information about new MS research to our subscribers around the world,” says Manners. “We’re expecting updates of important trials of oral drugs such as Gilenya, Aubagio and BG-12, as well as the infusion drugs such as Tysabri, alemtuzumab and daclizumab. This information is vital to help people make informed decisions about their treatment.”

    To prepare for the event, MSology recently polled its readers about the stories they’d like to see. “People have told us they want to learn more about BG-12, Gilenya, Tysabri and Copaxone,” St-Michel says. “But there’s a great deal of interest in other topics – such as the role viruses may play, factors that may affect disability progression and whether vitamin D supplements are worthwhile. We’ll be uniquely positioned to provide that information with our daily articles and ongoing Twitter feed. So stay tuned to msology.ca.”


Contact

Follow us on: Contact's Facebook Contact's Twitter

Attachments